Business Context and Reporting Period
Company: Creative Medical Technology Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 28, 2019 (Events reported on Feb 28 and March 1, 2019)
Context: The filing details two significant capital transactions: the exchange of existing warrants for convertible promissory notes and a new private placement of convertible notes and warrants to institutional investors.
Key Financial Metrics and Transaction Details
Transaction 1: Warrant Exchange (Feb 28, 2019)
- Instrument: Three Exchange Agreements converting warrants into Convertible Promissory Notes ("Exchange Notes").
- Principal Amount: $100,000 per note (Total principal not explicitly aggregated, but three separate agreements noted).
- Warrants Cancelled: Initially exercisable for an aggregate of 3,232,912 shares of common stock.
- Terms: 8% annual interest; matures Feb 28, 2020.
- Conversion: Convertible at 65% of the Market Price (defined as average of two lowest VWAPs over 15 trading days) after 31 days.
Transaction 2: Note and Warrant Purchase (March 1, 2019)
- Instrument: Sale of Convertible Notes and Warrants to four institutional investors.
- Capital Raised: $100,000 per investor (Total raised: $400,000).
- Note Principal: $110,000 per investor (Total principal: $440,000).
- Warrants Issued: 1,334,951 shares per investor (Total: 5,339,804 shares).
- Terms: 8% annual interest; matures March 1, 2020.
- Conversion: Convertible at 65% of the Market Price after 31 days.
- Warrant Exercise Price: $0.0206 per share (5-year term).
Material Changes vs. Prior Period
This filing represents a material change in the company's capital structure and debt obligations. The company has:
- Increased its direct financial obligations by issuing new convertible debt totaling at least $440,000 in principal from the new placement, plus the principal from the warrant exchanges.
- Eliminated the immediate dilution risk from 3,232,912 existing warrants by converting them into debt, while simultaneously creating new dilution potential through 5,339,804 new warrants and the conversion features of the new notes.
- Established a significant discount on future equity issuance, as both the Exchange Notes and new Notes convert at 65% of the prevailing market price.
Guidance, Outlook, and Risks
Management Commentary: The filing does not contain forward-looking guidance, earnings outlook, or general management commentary beyond the description of the executed agreements.
Risks and Contingencies:
- Dilution Risk: The conversion price of 65% of the Market Price creates a substantial discount, potentially leading to significant share dilution if the stock price rises or if notes are converted.
- Liquidity and Debt: The company has incurred new debt obligations maturing in 2020 with 8% interest rates. Failure to repay or convert could trigger default events.
- Market Price Definition: The "Market Price" is defined using the average of the two lowest VWAPs over a 15-day period, which may result in a lower conversion price than the current trading price, further increasing dilution.
Investor Verification Checklist
- Verify the total number of Exchange Notes issued and the aggregate principal amount owed from the warrant exchange.
- Confirm the current cash position of the company to assess its ability to service the 8% interest on the new debt obligations.
- Review the full text of Exhibits 10.1, 10.2, 4.1, 4.2, and 4.3 for specific covenants, default triggers, and redemption rights not detailed in the summary.
- Calculate the potential fully-diluted share count assuming immediate conversion of all notes and exercise of all warrants at the current market price.
- Check for any subsequent filings regarding the use of proceeds from the $400,000 raised in the March 1 transaction.